A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

NCT04511013 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

112

Enrollment

NETWORK

Sponsor class

Conditions

Acral Lentiginous Melanoma
Clinical Stage IV Cutaneous Melanoma AJCC v8
Metastatic Cutaneous Melanoma
Metastatic Malignant Neoplasm in the Brain
Metastatic Melanoma
Metastatic Mucosal Melanoma
Pathologic Stage IV Cutaneous Melanoma AJCC v8

Interventions

DRUG: Binimetinib
DRUG: Encorafenib
BIOLOGICAL: Ipilimumab
BIOLOGICAL: Nivolumab

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]